Recursion Pharmaceuticals (RXRX) investor relations material

Leadership transition and strategic priorities

• New CEO Najat Khan will focus on leveraging the integrated AI tech stack, building on platform insights, and demonstrating differentiated therapeutics over the next 12–18 months.

• Emphasis on maintaining operational discipline, with a 35% reduction in operating costs while preserving key external catalysts and partnerships.

• Talent and culture that combine AI and scientific expertise are seen as critical for future success.

• Chris Gibson transitions to chair of the board, expressing confidence in the new leadership.

Platform differentiation and AI integration

• Proprietary, large-scale in-house data generation underpins the AI models, differentiating from competitors reliant on public data.

• The Exscientia acquisition enhanced chemistry capabilities, supporting an end-to-end AI-driven platform from biology to clinical development.

• Over $500 million in partner revenue has been generated, reflecting the value of the proprietary data and AI stack.

• The company runs millions of experiments weekly, with 65 petabytes of data, 40 of which are proprietary.

• AI is used not just for discovery but also for clinical trial design and execution, a unique capability in the sector.

Regulatory engagement and clinical development

• Close engagement with regulators in the US and EU, leveraging board expertise from former FDA leadership.

• Focus on rare diseases and oncology, using multimodal data and causal AI to enhance early development and evidence generation.

• Early investment in predictive models and organoid systems supports reduced reliance on animal testing and aligns with evolving regulatory guidance.

• The FAP (Familial Adenomatous Polyposis) program is highlighted as a test case for regulatory innovation, with new data expected soon.